Helix BioMedix, Inc. (HXBM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Helix BioMedix, Inc. (HXBM) trades at $1.75 with AI Score 50/100 (Grade B). Helix BioMedix, Inc. is a biotechnology company specializing in bioactive peptides for skin health, focusing on dermatology and consumer products. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for HXBM: HXBM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HXBM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HXBM: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Helix BioMedix, Inc. (HXBM) Healthcare & Pipeline Overview
Helix BioMedix, Inc. is a biotechnology firm dedicated to developing innovative bioactive peptides for skin health, targeting dermatological applications and consumer products, with a unique focus on anti-infective and anti-inflammatory solutions.
What Is the Investment Thesis for HXBM?
Helix BioMedix, Inc. presents a unique investment thesis driven by its innovative bioactive peptide technology and its focus on skin health. The company operates in a niche market with significant growth potential, particularly in the cosmeceutical and wound care sectors, which are experiencing increasing demand due to rising awareness of skin health and infection prevention. With a gross margin of 99.4%, Helix BioMedix has the potential to achieve profitability as it scales its operations and expands its product offerings. Key growth catalysts include the successful commercialization of its peptide products and the establishment of strategic partnerships for out-licensing its technology. However, the company faces risks associated with its micro-cap status, including liquidity challenges and the need for additional funding to support its development pipeline. The ability to secure financing and achieve commercial milestones will be critical in determining the company's future performance.
Based on FMP financials and quantitative analysis
HXBM Key Highlights
Market Cap: $0.00B, indicating a micro-cap status with potential for growth.
- Profit Margin: -68.3%, highlighting current operational challenges.
- Gross Margin: 99.4%, demonstrating strong potential for profitability.
- Beta: 1.34, indicating higher volatility compared to the market.
- No dividend yield, reflecting a focus on reinvestment for growth.
Who Are HXBM's Competitors?
HXBM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HXBM's Key Strengths?
Innovative bioactive peptide technology.
- Strong gross margins indicating potential profitability.
- Niche focus on dermatology and skin health.
- Established brand recognition in the biotechnology sector.
What Are HXBM's Weaknesses?
Micro-cap status leading to liquidity challenges.
- Negative profit margin indicating operational difficulties.
- Limited resources with a small team of eight employees.
- Dependence on external funding for growth initiatives.
What Could Drive HXBM Stock Higher?
Potential partnerships for out-licensing its peptide technology.
- Continued development of bioactive peptides for skin health.
- Efforts to secure additional funding to support growth initiatives.
What Are the Key Risks for HXBM?
Negative return on equity (-30.4%) — the business is not currently generating profit on shareholder capital.
- Dependence on external funding for operational sustainability.
- Competition from larger, well-funded biotechnology firms.
- Regulatory challenges in bringing new products to market.
What Are the Growth Opportunities for HXBM?
- Growth opportunity 1: The global cosmeceutical market is projected to grow at a CAGR of 7.14% from 2021 to 2028, reaching $54.5 billion. Helix BioMedix's focus on bioactive peptides positions it to capitalize on this trend by developing innovative skincare products that meet consumer demand for effective, science-backed solutions.
- Growth opportunity 2: The wound care market is expected to expand significantly, with a projected CAGR of 6.5% from 2021 to 2028, reaching $22 billion. Helix BioMedix's anti-infective peptides can play a crucial role in this market, offering advanced treatment options for chronic wounds and infections.
- Growth opportunity 3: The increasing prevalence of skin infections, particularly those caused by antibiotic-resistant bacteria, presents a substantial opportunity for Helix BioMedix. The company's focus on anti-fungal and anti-inflammatory peptides can address these critical healthcare needs, potentially leading to partnerships with healthcare providers and institutions.
- Growth opportunity 4: Expansion into international markets can enhance Helix BioMedix's revenue streams. As global awareness of skin health and infection prevention rises, the company can leverage its proprietary technology to enter new markets, particularly in regions with growing healthcare infrastructure.
- Growth opportunity 5: Strategic partnerships and collaborations with larger pharmaceutical companies can provide Helix BioMedix with the necessary resources and market access to scale its operations. By out-licensing its peptides, the company can generate additional revenue while focusing on its core research and development initiatives.
What Threats Does HXBM Face?
- Intense competition from larger biotechnology firms.
- Regulatory challenges in bringing new products to market.
- Market volatility affecting funding and investment.
- Potential patent expiration risks impacting product exclusivity.
What Are HXBM's Competitive Advantages?
- Unique proprietary peptide technology that differentiates its products.
- Strong gross margin of 99.4%, indicating pricing power.
- Established expertise in bioactive peptide development.
- Focus on niche markets with high barriers to entry.
- Potential for strategic partnerships enhancing market access.
What Does HXBM Do?
Helix BioMedix, Inc., founded in 1988, is a biotechnology company based in Bothell, Washington, that specializes in the development and commercialization of bioactive peptides aimed at enhancing skin health. The company operates primarily in the dermatology and consumer products sectors, focusing on innovative solutions for skin and wound infections. Its product portfolio includes anti-infective, anti-fungal, and anti-inflammatory peptides designed to treat various skin conditions and prevent infections, particularly those caused by staphylococcus aureus. Helix BioMedix also engages in out-licensing its proprietary peptides to other entities, thereby expanding its market reach and potential revenue streams. Over the years, the company has positioned itself as a niche player in the biotechnology landscape, leveraging its unique keratin-based technology to differentiate its offerings. With a small team of eight employees, Helix BioMedix operates with a lean structure, allowing for agile decision-making and innovation. The company's commitment to research and development is evident in its ongoing efforts to explore novel applications for its peptide technology, which could lead to new therapeutic solutions in the cosmeceutical and wound care markets. As it navigates the competitive landscape of biotechnology, Helix BioMedix aims to establish itself as a leader in skin health solutions, addressing unmet needs in the dermatological space.
What Products and Services Does HXBM Offer?
- Develops bioactive peptides for skin health applications.
- Focuses on anti-infective, anti-fungal, and anti-inflammatory peptides.
- Targets treatment for skin and wound infections.
- Prevents infections caused by staphylococcus aureus.
- Out-licenses proprietary peptides to various entities.
- Operates primarily in the dermatology and consumer products sectors.
How Does HXBM Make Money?
- Generates revenue through the commercialization of bioactive peptides.
- Out-licenses proprietary technology to other companies.
- Engages in research and development to innovate new products.
- Focuses on niche markets within the dermatology sector.
- Seeks partnerships to enhance distribution and market reach.
What Industry Does HXBM Operate In?
The biotechnology industry, particularly in the healthcare sector, is witnessing significant growth driven by advancements in technology and increasing consumer demand for innovative health solutions. Within this landscape, Helix BioMedix, Inc. operates as a specialized player, focusing on bioactive peptides that cater to dermatological applications. The competitive landscape includes various biotechnology firms, but Helix BioMedix's unique peptide technology positions it favorably to capture market share in the cosmeceutical and wound care segments.
Who Are HXBM's Key Customers?
- Healthcare providers seeking advanced treatment options for skin infections.
- Consumers looking for effective skincare products.
- Pharmaceutical companies interested in licensing bioactive peptides.
- Research institutions exploring innovative dermatological solutions.
- Wound care specialists requiring effective infection prevention methods.
How Helix BioMedix, Inc. Is Valued
Relative to its peer group, HXBM's quantitative score of 50/100 is below the peer average of 80/100.
Company Profile
Helix BioMedix, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bothell, US. The company is led by CEO Robin L. Carmichael. HXBM has traded publicly since 1999.
Key Financial Metrics
Return on equity for Helix BioMedix, Inc. stands at -30.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.9%, showing how much profit it generates from its asset base. A current ratio of 12.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -137.1%, the inverse of the P/E and a quick read on earnings relative to price.
HXBM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Helix BioMedix's future prospects, which often signals a positive outlook.
- Community sentiment has shifted positively, with increasing discussions around the potential of their innovative products.
- Recent partnerships have enhanced the company's credibility, attracting positive attention from both investors and industry analysts.
- The growing demand for biotech solutions in health and wellness sectors positions Helix BioMedix favorably in an expanding market.
Bear Case
- Concerns about regulatory hurdles have been raised, as navigating the biotech landscape can be challenging and time-consuming.
- Some community members express skepticism about the scalability of Helix BioMedix's technology, fearing it may not meet market demands.
- Recent market volatility has led to cautious sentiment, with investors wary of smaller biotech firms amid economic uncertainties.
- Competitors are ramping up their R&D efforts, potentially overshadowing Helix BioMedix's advancements and impacting its market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HXBM Latest News
No recent news available for HXBM.
HXBM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HXBM.
Price Targets
Wall Street price target analysis for HXBM.
HXBM MoonshotScore
What does this score mean?
The MoonshotScore rates HXBM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robin L. Carmichael
CEO
Robin L. Carmichael has been leading Helix BioMedix, Inc. since its inception in 1988. With a strong background in biotechnology and a focus on dermatological applications, she has been instrumental in guiding the company's strategic direction. Carmichael holds a degree in Biochemistry and has extensive experience in product development and commercialization within the biotech sector.
Track Record: Under Carmichael's leadership, Helix BioMedix has developed a unique portfolio of bioactive peptides, positioning the company as a key player in the dermatology market. Her strategic vision has led to successful collaborations and licensing agreements, enhancing the company's market presence.
HXBM OTC Market Information
The OTC Other tier represents companies that do not meet the more stringent requirements for the OTCQX or OTCQB tiers. This tier includes a wide range of companies, often with lower trading volumes and less regulatory oversight compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial transparency compared to larger public companies.
- Higher volatility and price fluctuations due to lower trading volumes.
- Potential for dilution if the company seeks additional funding.
- Increased risk of fraud or mismanagement in less regulated environments.
- Verify the company's financial health through available reports.
- Assess the management team's track record and experience.
- Evaluate the competitive landscape and market positioning.
- Investigate any pending legal or regulatory issues.
- Review product pipeline and development timelines.
- Established history since 1988, indicating longevity in the market.
- Proprietary technology with potential for unique applications.
- Engagement in out-licensing, suggesting interest from other entities.
What Investors Ask About Helix BioMedix, Inc. (HXBM) — Healthcare
What does the AI Score mean for HXBM?
HXBM holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Helix BioMedix, Inc. is a biotechnology company specializing in bioactive peptides for skin health, focusing on dermatology and consumer products. Founded in 1988, it operates from Bothell …
What does Helix BioMedix, Inc. do?
Helix BioMedix, Inc. specializes in developing bioactive peptides aimed at enhancing skin health. The company focuses on creating innovative solutions for skin and wound infections, particularly targeting anti-infective, anti-fungal, and anti-inflammatory applications. By leveraging proprietary technology, Helix BioMedix aims to address unmet needs in the dermatological market.
What are the main risks for HXBM?
Helix BioMedix faces several risks, including its micro-cap status, which may lead to liquidity challenges and dependence on external funding. Additionally, the company operates in a competitive landscape dominated by larger biotechnology firms, posing threats to its market share. Regulatory hurdles in product development and commercialization further add to the risk profile, necessitating careful monitoring of the company's progress.
How does Helix BioMedix, Inc. manage patent expiration risks?
Helix BioMedix actively engages in research and development to innovate and expand its product portfolio, which helps mitigate risks associated with patent expirations. By continuously exploring new applications for its proprietary peptides and seeking out licensing agreements, the company aims to maintain a competitive edge and extend its market presence even as existing patents reach their expiration dates.
What are the key factors to evaluate for HXBM?
Helix BioMedix, Inc. (HXBM) holds an AI score of 50/100 (moderate). presents a unique investment thesis driven by its innovative bioactive peptide technology and its focus on skin health. Not financial advice.
How frequently does HXBM data refresh on this page?
HXBM's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HXBM's recent stock price performance?
Helix BioMedix, Inc. (HXBM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative bioactive peptide technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HXBM overvalued or undervalued right now?
Helix BioMedix, Inc. (HXBM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HXBM before investing?
Before investing in Helix BioMedix, Inc. (HXBM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available company information and may be subject to change.